CNA Financial Corporation will release its third quarter 2026 earnings on November 2, 2026, before the market opens. The company will provide a news release, earnings presentation, and financial supplement on its website. Management, including the CEO and CFO, will share commentary and answer pre-submitted questions from shareholders and analysts. CNA is a major U.S. commercial property and casualty insurer with over 125 years of experience, serving clients in the U.S., Canada, and Europe.
CNA Financial's upcoming third quarter 2026 results provide context for financial sector activity. For readers following the financial sector, here is Pluang's market snapshot as of Oct 13, 2026 20:51 WIB: out of 118 priced US financial stocks, 59 rose and 57 fell. Notable movers include Nu Holdings Ltd at USD 15.66 with a 1-day change of -2.19%, Banco Bradesco Sa at USD 4.19 with 100% buy order activity, and XP Inc. Class A at USD 31.92 with a 1-day change of -2.09%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
